Last checked at 14 Aug 2023 07:00
Notice of Interim Results
Oxford, UK - 14 August 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, will be announcing its interim results for the six months ended 30 June 2023 on Wednesday 20 September 2023.
At the forthcoming interim results, the Company, under the leadership of new Chief Executive Officer, Dr Frank Mathias, will discuss the implementation plan for its pure-play CDMO strategy and growth prospects, including medium-term financial guidance. The Company will also introduce its Chief Commercial Officer, Dr Sebastien Ribault, who joined the Company from Merck KGaA in November 2022. Dr Ribault will discuss the Company's client portfolio and commercial strategy, including its new business pipeline and the structure of its expanded global commercial team.
The Company will host an extended briefing for analysts and investors from 13:00 BST / 8:00 ET for 90 minutes both face to face in London and virtually via a webcast. The leadership team consisting of Dr Frank Mathias, Chief Executive Officer, Stuart Paynter, Chief Financial Officer, and Dr Sebastien Ribault, Chief Commercial Officer, will hold a presentation and take part in a live Q&A session. A replay of the webcast will be made available shortly afterwards.
For more details, please contact Consilium Strategic Communications.
-Ends-
Enquiries:
Oxford Biomedica plc:
Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E: ir@oxb.com
Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E: ir@oxb.com
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn and YouTube.